United States: CDC Issues New Guidelines For Opioid Prescriptions

Last Updated: February 16 2018
Article by Charles G. Hoey

The opioid crisis in America is frequently in the news and should be.  Opioids have caused an enormous cost increase for workers’ compensation employers and insurers.  Some cases are impossible to settle because a Medicare Set Aside trust (“MSA”) is required, and the cost of the MSA is $500,000 or more due primarily to the projections of opioid medications for the remainder of the claimant’s life.  The Center for Disease Control (“CDC”) recently issued guidelines for prescribing opioids for chronic pain.  A copy of those guidelines is attached.  The CDC is attempting to effect an enormous change in how opioids are used.

Here are the high points:  “Opioids are not first line or retained therapy for chronic pain.”  Although opioids can be appropriate for acute pain immediately after an injury, “clinicians should prescribe the lowest effective dose of immediate release opioids and prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids.  According to the guidelines, three days or less will often be sufficient; more than seven days will rarely be needed.

The other guidelines discuss the need for frequent drug screens, and discontinuing opioids after a few weeks, if there is no meaningful improvement in pain and function.  Physicians should also review a patient’s history, if any, for the use of any addictive narcotic medications or drugs. Before prescribing medications, doctors should go online to use state prescription drug databases.   

According to these guidelines, opioids are for acute pain immediately after a severe injury or trauma, or end of life care.  Opioids are not for treatment of long term chronic pain. 

Remember:  these guidelines are only suggestions and do not have the force of law.  Many doctors will continue to prescribe opioids and maintain that they are useful for the treatment of chronic pain.  At a minimum, those doctors should be getting frequent urine drug screens from their patients, with confirmation testing of the drug screens.  Doctors should also assess if the opioids are reducing pain and improving function.

Pre-employment and random drug screens should include testing for opioids as well as any drug screens done immediately after an injury.  Remember that someone that has just suffered a severe injury may have opioids in his or her system from medications immediately given after the injury.  The confirmation drug testing can distinguish between the presence of opioids which have been in a person’s system for several days versus opioids taken within the past few hours.

RECOMMENDATIONS FOR NEW CLAIMS

With new claims, try to keep claimants off opioids after the first three to seven days.  If an authorized treating physician insists on prescribing opioids for more than three to seven days, it is appropriate to forward the CDC guidelines to the treating physician, ask whether he or she intends to perform frequent drug screens, and whether the doctor will assess the benefits of the treatment within one to four weeks.  As you know, many doctors simply start prescribing opioids and likely have the expectation that the patient will be on opioids for months or years.  Even if opioids are tried as a treatment for chronic pain, they should not be continued if there is no improvement in pain and function within the first few weeks or months.  Even if the patient insists that the pain is reduced from the opioids, the doctor should also be checking or clinical and objective signs of improved function.  Subjective reports from the patient that the opioids are helping should not be sufficient to warrant continuing prescriptions.  Although doctors are not required to follow the CDC guidelines, the guidelines provide a reasonable basis for questioning doctors who seem to offer little more than chronic use of opioids. 

Doctors who do not use opioids have to provide other treatment options.  This treatment will likely take the form of physical therapy, work hardening conditioning, or injections.  Another opinion is psychological treatment specifically designed to help a patient cope with pain.  There has been, and likely will continue to be, reluctance to include psychological counseling for pre-existing as part of a pain management program.  This treatment must be specifically designed to help an injured patient learn to live with chronic pain and/or disabilities rather than a “blank check” to treat unrelated conditions. 

RECOMMENDATIONS FOR PATIENTS ALREADY TAKING OPIOIDS

For patients who have been on opioids for years, the solution is not to simply stop authorizing the medications.  Patient cannot go “cold turkey.”  Some patients will be difficult to wean from opioids.  There are several strategies which may be successful.  Get a second opinion with a physician who is known to wean patients from opioids and who offers treatment options other than pills.  Peer review or utilization review could be an option.  Insist the patient be required to undergo frequent drug screens.  According to the guidelines, if the opioids are not helping, the solution is not to increase the dosage.  The solution is to try another form of treatment.  Also, make sure the doctor responds appropriately to inconsistent drug screen results.

Other options include filing a motion for a change in authorized treating physician or asking the treating physician if he or she will consider switching a patient with opioid use disorder to medications such as Buprenorphine, Methadone, or Naloxone. 

The over prescription of opioids will likely continue to be a problem.  Fortunately, the CDC guidelines, and the studies and research upon which these guidelines are based, can help give employer/insurers a reasonable basis to prevent opioid addiction and to argue for weaning some chronic opioid users from these medications. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Charles G. Hoey
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions